Please assess the completion status of the following clinical trial:

Trial Title: Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who have given their written consent in a free and informed consent~* Patient followed for inflammatory bowel disease (Crohn's disease, ulcerative colitis or indeterminate colitis), and treated for at least 3 months by immunosuppressive therapy and /or biotherapies and in clinical remission for at least 3 months~* Patient agreeing to participate in the study throughout its duration and accepting the procedures related to the study~* Contraception that the investigator judges effective for the first 12 months of the trial, with a negative pregnancy test~* Women not planning to become pregnant in the 12 months following inclusion (M0)~* Patient with social coverage~Exclusion Criteria:~* Patients vaccinated against pneumo23 for less than 5 years~* Other vaccination during the month before inclusion~* Patient develops a febrile illness (at least 37 ° C 5 measured orally) or acute infection in the week before vaccination~* The patient has a flare up of IBD the day of vaccination (Harvey-Brasdshaw score of at least 6 or CDAI \> 220 for Crohn's disease or Mayo Clinic score of at least 4 for UC and indeterminate colitis)~* Patients with an ongoing pregnancy the day of vaccination~* Patient with a known history of neuropathy as Guillain-Barré syndrome.~* Patients with known infection with HIV and / or HBV (HBsAg positive) and / or HCV~* Patient with other severe immune deficiency~* Patients who received immunoglobulin infusions of blood products, or of monoclonal antibodies (except anti-TNF) in the 3 months prior to vaccination~* Patient institutionalized, or deprived of liberty administrative or judicial~* Patients treated without immunosuppressive therapy or biotherapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 dose Prevenar13 and 1 dose PSV23 (Type: ACTIVE_COMPARATOR): one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
- 2 doses Prevenar13 and 1 dose PSV23 (Type: EXPERIMENTAL): one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4

Based on this trial design, predict the completion outcome and termination type (if applicable).